title: Potent vasorelaxant activity of the TMEM16A inhibitor T16A(inh) -A01.
abstract: OBJECTIVE
  T16A(inh) -A01 is a recently identified inhibitor of the calcium-activated chloride channel TMEM16A. The aim of this study was to test the efficacy of T16A(inh) -A01 for inhibition of calcium-activated chloride channels in vascular smooth muscle and consequent effects on vascular tone.
  
  
  METHODS
  Single channel and whole cell patch clamp was performed on single smooth muscle cells from rabbit pulmonary artery and mouse thoracic aorta. Isometric tension studies were performed on mouse thoracic aorta and mesenteric artery as well as human abdominal visceral adipose artery.
  
  
  RESULTS
  In rabbit pulmonary artery myocytes T16A(inh) -A01 (1-30 μM) inhibited single calcium (Ca(2+) )-activated chloride (Cl(-) ) channels and whole cell currents activated by 500 nM free Ca(2+) . Similar effects were observed for single Ca(2+) -activated Cl(-)  channels in mouse thoracic aorta, and in both cell types, channel activity was abolished by two antisera raised against TMEM16A but not by a bestrophin antibody. The TMEM16A potentiator, F(act)  (10 μM), increased single channel and whole cell Ca(2+) -activated Cl(-)  currents in rabbit pulmonary arteries. In isometric tension studies, T16A(inh) -A01 relaxed mouse thoracic aorta pre-contracted with methoxamine with an IC(50)  of 1.6 μM and suppressed the methoxamine concentration-effect curve. T16A(inh) -A01 did not affect the maximal contraction produced by 60 mM KCl and the relaxant effect of 10 μM T16A(inh) -A01 was not altered by incubation of mouse thoracic aorta in a cocktail of potassium (K(+) ) channel blockers. T16A(inh) -A01 (10 μM) also relaxed human visceral adipose arteries by 88 ± 3%.
  
  
  CONCLUSIONS
  T16A(inh) -A01 blocks calcium-activated chloride channels in vascular smooth muscle cells and relaxes murine and human blood vessels.
authors.affiliation: Pharmacology and Cell Physiology Research Group, Division of Biomedical Sciences, St George's, University of London, London, UK.
authors.forename: Alison J
authors.initials: AJ
authors.lastname: Davis
authors.forename: Jian
authors.initials: J
authors.lastname: Shi
authors.forename: Harry A T
authors.initials: HA
authors.lastname: Pritchard
authors.forename: Preet S
authors.initials: PS
authors.lastname: Chadha
authors.forename: Normand
authors.initials: N
authors.lastname: Leblanc
authors.forename: Georgios
authors.initials: G
authors.lastname: Vasilikostas
authors.forename: Zhen
authors.initials: Z
authors.lastname: Yao
authors.forename: A S
authors.initials: AS
authors.lastname: Verkman
authors.forename: Anthony P
authors.initials: AP
authors.lastname: Albert
authors.forename: Iain A
authors.initials: IA
authors.lastname: Greenwood
mesh_terms: D000273:Adipose Tissue / Q000098:blood supply / Q000502:physiology; D000818:Animals; D000075369:Anoctamin-1; D001013:Aorta, Thoracic / Q000166:cytology / Q000502:physiology; D018118:Chloride Channels / Q000037:antagonists & inhibitors* / Q000502:physiology; D006801:Humans; D008638:Mesenteric Arteries / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008807:Mice, Inbred BALB C; D032389:Myocytes, Smooth Muscle / Q000187:drug effects* / Q000502:physiology; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D011651:Pulmonary Artery / Q000166:cytology / Q000502:physiology; D011743:Pyrimidines / Q000494:pharmacology*; D011817:Rabbits; D013844:Thiazoles / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: C476213:ANO1 protein, human; C531181:ANO1 protein, mouse; D000075369:Anoctamin-1; D018118:Chloride Channels; D009363:Neoplasm Proteins; D011743:Pyrimidines; C578466:T16AInh-A01; D013844:Thiazoles; D014665:Vasodilator Agents